Poor angioplasty sales drag down Pfizer's results
This article was originally published in Clinica
Declining sales of Pfizer's angioplasty and urology products led to flat growth in the company's medical technology sector, where sales rose only 1% to $1.5 billion in 1997. The company attributes this to pricing pressures and new product competition.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.